Niagen Bioscience, Inc. 8-K

What Happened
Niagen Bioscience, Inc. (filed 8-K Feb 26, 2026) announced that ChromaDex, Inc. and ChromaDex Analytics, Inc. (each wholly owned subsidiaries) and Niagen (as guarantor) sold substantially all assets of their analytical reference standards and services business to VHG Labs, Incorporated (part of LGC Group). The Asset Purchase Agreement was signed and the transaction closed on February 24, 2026. The deal is described as an all-cash transaction subject to customary adjustments. A press release dated February 26, 2026 was furnished as Exhibit 99.1.

Key Details

• Transaction signed and closed: February 24, 2026.
• Buyer: VHG Labs, Incorporated (part of LGC Group).
• Assets sold: substantially all assets comprising the Sellers’ analytical reference standards and services business; Niagen acted as guarantor for certain provisions.
• Consideration and terms: described as an all-cash sale "subject to customary adjustments"; purchase price not disclosed in the filing.
• Transition services: Sellers will provide operational and administrative transition services for up to six months post-close and will receive a service fee recognized as services are performed.

Why It Matters
This divestiture is part of Niagen’s stated strategy to exit non-core activities and focus resources on its NAD+ science platform, intellectual property, and commercial growth initiatives. The sale removes a non-core business line and brings immediate cash proceeds (amount undisclosed), plus short-term transition revenue from service fees. Investors should note the company did not disclose the purchase price or any expected one-time gain/loss in this 8-K; any financial impact will appear in future disclosures.